Hsbc Holdings PLC Boosts Position in LivaNova PLC $LIVN

Hsbc Holdings PLC raised its position in LivaNova PLC (NASDAQ:LIVN) by 260.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,301 shares of the company’s stock after purchasing an additional 14,671 shares during the period. Hsbc Holdings PLC’s holdings in LivaNova were worth $1,255,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Hantz Financial Services Inc. raised its stake in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares during the last quarter. State of Wyoming acquired a new position in shares of LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC lifted its stake in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares in the last quarter. Quarry LP purchased a new stake in LivaNova in the 3rd quarter valued at approximately $36,000. Finally, Covestor Ltd grew its holdings in LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.35% of the company’s stock.

LivaNova Trading Up 0.3%

Shares of LIVN opened at $82.48 on Thursday. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $83.98. The firm has a market capitalization of $4.53 billion, a P/E ratio of 42.30 and a beta of 0.86. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The stock’s fifty day simple moving average is $73.20 and its 200 day simple moving average is $67.36.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same period in the previous year, the company posted $0.88 EPS. The company’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts forecast that LivaNova PLC will post 3.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Robert W. Baird cut their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Mizuho upped their target price on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. KeyCorp raised their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Finally, Barclays lifted their price target on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $80.75.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.